Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Infliximab for Immune Checkpoint Inhibitor Associated Acute Kidney Injury: A Pilot Randomized Clinical Trial

NCT07683975 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT07683975
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07683975 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Infliximab for Immune Checkpoint Inhibitor Associated Acute Kidney Injury: A Pilot Randomized Clinical Trial
Lead sponsor
Massachusetts General Hospital
Phase
Phase 4
Overall status
Recruiting
Start date
September 15, 2026
Completion date
July 16, 2029
Enrollment
44 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acute interstitial nephritis, acute kidney injury